SIWA Therapeutics, Inc. Presents New Data at the November 2022 American Association for Cancer Research Aging and Cancer Conference
You can view the poster by clicking here.Chicago, IL., November 21, 2022, The aging-related and cancer cell-derived oxidatively-stressed tumor microenvironment and other cell damages drive cell senescence and other oxidative cellular responses. Tumor fibrosis reduces the effectiveness of anti-cancer immune responses and senescent cells (SCs), in turn, promote immune suppression, tumor progression, and metastasis. Hence, according to a study conducted by Translational Genomics Research Institute on behalf of SIWA Therapeutics, Inc. as presented by Dr. Gabriela Rossi, Chief Research Officer of SIWA Therapeutics, Inc. (“SIWA”) at the AACR Special Conference: Aging and Cancer November 17 -20, 2022, targeting damaged cells, including SCs and cancer cells, with SIWA318H, presents an attractive approach for cancer therapy. SIWA318H is a monoclonal antibody that selectively targets an advanced glycation end product oxidative stress biomarker…